改变的关键在于我省推进紧密型县域医共体建设——以市县人民医院为牵头单位，联合乡镇卫生 院、村卫生室等基层医疗机构，形成统一管理单元。"最核心的变化是统一了药品目录，彻底打通了用 药限制。"蔡捷捷介绍，此举显著增加了乡镇卫生院和村卫生室的可用药品种类，让慢病患者能够便捷 地在"家门口"用上所需的药品。 新政策的成效已开始在基层显现。"我们卫生院通过对辖区患者需求的细致摸底，将降压药品种从 过去的几种扩展到现在的十多种，基本覆盖了附近患者的常用药需求。"蔡捷捷院长介绍，这意味着更 多的患者可以免除奔波之苦，真正享受就近的基层医疗服务。 近日，海口市云龙镇长泰村卫生室医生王运铭看着身患高血压病的村民蔡夫丰的检查报告，对照着 一条条数据进行讲解。在了解了他的常用药后，王运铭当场为他开具了降压药。以往，蔡夫丰需要到海 口市第五人民医院取药，如今在家门口的村卫生室就可以拿到这些药。 自深入贯彻中央八项规定精神学习教育开展以来，省卫生健康委坚持学查改、开门教育一体推进， 教育引导党员干部主动担当作为，坚持把脉问诊、对症下药，聚焦百姓看病的"关键事、揪心事"精准发 力，积极推进为民办实事事项，以作风建设新成效提升群众就医获得 ...

Core Insights - The 2025 Xiamen Talent Service Month aims to attract global talent to foster innovation and development in the city [1][2] - The event emphasizes practical matchmaking between talent and enterprises, focusing on technological achievements [2] Talent Initiatives - Xiamen has established global talent workstations to facilitate the flow of international professionals, including the "Heart Sapling Visiting Scholar Program" by Xiamen Cardiovascular Hospital [3] - The program has formed strategic partnerships with leading medical institutions in six countries, attracting 26 young physicians for training [4] Policy and Support - Xiamen introduced the "Eight-point Policy on AI Industry Talent Development" to enhance support for professionals in key areas such as recruitment and cultivation [5] - The "Top 10 AI+Talent Application Scenarios" were also introduced, aligning AI technologies with talent services in various sectors [6] International Engagement - Xiamen has hosted overseas entrepreneurship competitions for seven consecutive years, enhancing its global talent attraction [7] - The inaugural Global Innovation and Entrepreneurship Competition seeks leading talent projects in innovative fields, with over 300 projects registered from nearly 20 countries [8]

Core Viewpoint - Kahn Swick & Foti, LLC is investigating iRhythm Technologies, Inc. following a Warning Letter from the FDA regarding non-conformities in medical device regulations and subsequent legal actions against the company and its executives [1][2][3]. Group 1: FDA Warning and Compliance Issues - On May 30, 2023, iRhythm Technologies received a Warning Letter from the FDA concerning non-conformities related to the Zio AT System, specifically addressing deficiencies in medical device reporting and quality system requirements [2]. - The FDA's concerns included undisclosed risks to patients, such as limitations in the transmission of arrhythmia or heart irregularity events [2]. Group 2: Legal Actions and Investigations - Following the FDA's Warning Letter, iRhythm and certain executives were sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws [3]. - The court has denied the company's motion to dismiss the case, allowing the lawsuit to proceed, while KSF's investigation focuses on potential breaches of fiduciary duties by iRhythm's officers and directors [3].

In the latest trading session, Abbott (ABT) closed at $132.02, marking a -1.18% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.33%. Meanwhile, the Dow experienced a drop of 0.63%, and the technology-dominated Nasdaq saw a decrease of 0.22%. Prior to today's trading, shares of the maker of infant formula, medical devices and drugs had lost 2.09% lagged the Medical sector's loss of 0.32% and the S&P 500's gain of 4.07%.The investment community will be paying close ...

Company Performance - Intuitive Surgical, Inc. (ISRG) stock was down 2.66% at $512.06, underperforming the S&P 500's daily loss of 0.33% [1] - Over the previous month, ISRG shares gained 2.54%, outperforming the Medical sector's loss of 0.32% but underperforming the S&P 500's gain of 4.07% [1] Upcoming Earnings - The upcoming earnings report for Intuitive Surgical is expected on July 22, 2025, with a forecasted EPS of $1.92, reflecting a 7.87% increase from the same quarter last year [2] - Revenue is projected at $2.35 billion, indicating a 16.81% rise from the equivalent quarter last year [2] Full Year Estimates - For the full year, earnings are projected at $7.84 per share and revenue at $9.65 billion, showing increases of +6.81% and +15.56% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Intuitive Surgical reflect short-term business trends, with positive revisions indicating optimism about the business outlook [3] Zacks Rank - Intuitive Surgical is currently rated as Zacks Rank 2 (Buy), with the Zacks Rank system showing a strong track record of performance [5] Valuation Metrics - The company has a Forward P/E ratio of 67.09, significantly higher than the industry average of 23.76 [6] - The PEG ratio for ISRG is 4.44, compared to the Medical - Instruments industry's average PEG ratio of 2.29 [6] Industry Overview - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 168, placing it in the bottom 32% of over 250 industries [7] - Top-rated industries (top 50%) outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - Moderna's stock closed at $33.64, down 1.87%, underperforming the S&P 500's daily loss of 0.33% [1] - Over the previous month, Moderna's shares gained 25.34%, outperforming the Medical sector's loss of 0.32% and the S&P 500's gain of 4.07% [1] Upcoming Earnings - The upcoming earnings release is anticipated, with an expected EPS of -$2.97, reflecting a 10.81% increase from the same quarter last year [2] - Revenue is forecasted at $130.15 million, indicating a 46% decline compared to the same quarter last year [2] Full-Year Estimates - Zacks Consensus Estimates predict full-year earnings of -$9.81 per share and revenue of $2.08 billion, representing year-over-year changes of -10.6% and -35.83%, respectively [3] - Recent changes in analyst estimates are crucial for investors, as positive revisions indicate optimism regarding business and profitability [3] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown a strong track record, with 1 stocks delivering an average annual return of +25% since 1988 [5] - Currently, Moderna holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate moving 0.26% lower over the last 30 days [5] Industry Overview - The Medical - Biomedical and Genetics industry ranks in the top 31% of all industries, with a current Zacks Industry Rank of 76 [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Core Viewpoint - Movano Health has received a delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement and late filing of its Form 10-Q for the quarter ended March 31, 2025 [1][2]. Group 1: Delisting Notice Details - The company was notified on July 7, 2025, that its common stock's closing bid price had fallen below $1.00 per share for 30 consecutive trading days, violating the Bid Price Requirement [2]. - The company is not eligible for any compliance period due to a reverse stock split that occurred within the prior year [2]. - Movano Health plans to request a hearing before a Nasdaq Hearings Panel to contest the delisting and intends to seek an extended stay of suspension during the hearings process [1][3]. Group 2: Company Background - Movano Health, founded in 2018, focuses on developing healthcare solutions that provide medical-grade data through wearable devices [4]. - The company's technologies aim to proactively monitor and manage health outcomes across various patient populations [5].

ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) complied with federal securities laws. On July 8, 2025, RxSight announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance, revealing declines in revenue, Light Delivery Devices sales, and usage of Light Adjustable Lenses. Following this news, the price of the Company’s stock dropped.  If you purchased RxSight s ...

Core Insights - Certara, Inc. is positioned to potentially continue its earnings-beat streak in the upcoming report, having surpassed earnings estimates by an average of 11.54% in the last two quarters [1][2]. Earnings Performance - In the last reported quarter, Certara achieved earnings of $0.14 per share, exceeding the Zacks Consensus Estimate of $0.13 per share, resulting in a surprise of 7.69% [2]. - In the previous quarter, the company was expected to post earnings of $0.13 per share but delivered $0.15 per share, leading to a surprise of 15.38% [2]. Earnings Estimates and Predictions - Recent estimates for Certara have been trending upward, with a positive Earnings ESP of +2.44%, indicating increased analyst optimism regarding the company's earnings prospects [5][8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a high likelihood of another earnings beat, with historical data showing that stocks with this combination beat estimates nearly 70% of the time [6][8]. Earnings ESP Explanation - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate [7]. - A negative Earnings ESP can reduce the predictive power of the metric, but it does not necessarily indicate an earnings miss [9]. Importance of Earnings ESP - Many companies beat consensus EPS estimates, but this is not the sole reason for share price gains; thus, checking a company's Earnings ESP before quarterly releases is crucial for investment decisions [10].

Demographic Shift and Healthcare Demand - The world is experiencing a significant demographic shift with populations aging rapidly, where individuals aged 60 and older outnumber children under five for the first time in 2020, projected to exceed 2 billion by 2050 [2] - The U.S. population aged 65 and older is expected to nearly double by 2050, with those aged 85 and older projected to triple by 2060 [2] Geriatric Care Market Growth - The global geriatric care services market, valued at $1 trillion in 2022, is expected to more than double by 2033, driven by growth in pharmaceuticals, medical devices, long-term and home-based care, and digital health solutions [3] Healthcare Challenges in the U.S. - Mortality rates among seniors have increased by 4.5% annually, with a 50% rise for those aged 85 and older; Alzheimer's and dementia-related deaths are up 40% [4] - Hospital utilization is surging, with admissions rising by 25%, average stay lengthening, readmissions increasing by 20%, and emergency visits soaring by 40% [4] Pharmaceutical and Device Companies' Response - Pharmaceutical firms like Roche and Novo Nordisk are focusing on high-demand areas, while device makers such as Edwards Lifesciences and Stryker are advancing tools for chronic disease management [5] Digital Health Innovations - Digital health is transforming elder care with AI-powered diagnostics, remote monitoring, and wearables, leading to better outcomes and new revenue models [6] - The demand for home care is rising as more seniors choose to age at home, although a projected shortage of 2.3 million long-term care workers by 2030 poses challenges [6] Financial Trends in Senior Care - U.S. senior care spending exceeded $1 trillion in 2022 and could double by 2040, emphasizing the need for value-based models and efficient chronic disease management [7] Roche's Strategic Initiatives - Roche is advancing Alzheimer's diagnostics with the Elecsys Amyloid Plasma Panel, showing 91% sensitivity and 96.2% negative predictive value, and has announced a $50 billion investment in U.S. operations over five years [8][9] Novo Nordisk's Regulatory Wins - Novo Nordisk's Ozempic received FDA approval for reducing kidney disease progression and cardiovascular death in adults with Type 2 diabetes, and the company is investing €2.34 billion to upgrade its production facility in Italy [10][11] Edwards Lifesciences' Innovations - Edwards Lifesciences is focusing on aortic stenosis care, with new data showing early treatment reduces costs and improves outcomes; TAVR sales reached $1.05 billion in Q1 2025 [12][13] Stryker's Market Penetration - Stryker is making strategic investments in senior healthcare, enhancing capabilities in minimally invasive neurosurgery through acquisitions, and offering products designed to improve outcomes for elderly patients [14][15]